Genshin Impact banners rotate every few weeks on a precise schedule, and we always know what to expect thanks to regular updates from Hoyoverse. The developer of the anime game always keeps its ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

The Honkai Star Rail banner schedule provides a selection of useful information for players, as it shows both the current warp events that are running right now so you know what rewards are ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...